Saiyed Mahmood
Director/Board Member at F2G Ltd.
Profile
Saiyed Kaasim Mahmood is currently a Non-Executive Director at F2G Ltd., a Director at NeRRe Therapeutics Ltd., a Non-Executive Director at Orphalan SA, and a Director at KaNDy Therapeutics Ltd.
He previously held the position of Director at NeRRe Therapeutics Holdings Ltd.
starting in 2017.
Prior to that, he was a General Partner at Advent.
Venture Partners LLP starting in 2012.
Dr. Mahmood has also held positions as a Director at Axonics Women's Health Ltd.
from 2011 to 2013, a Director at Nicoventures Trading Ltd., and a Principal at Cutfield Freeman & Co. Ltd.
He obtained a doctorate degree from University College London.
Saiyed Mahmood active positions
Companies | Position | Start |
---|---|---|
Advent Venture Partners LLP
Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Private Equity Investor | 31/05/2005 |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Director/Board Member | - |
NeRRe Therapeutics Ltd.
NeRRe Therapeutics Ltd. Medical DistributorsDistribution Services NeRRe Therapeutics Ltd. provides clinical and pre clinical drugs for treatment of neuronal hypersensitivity. It develops neurokinin receptor antagonists acquired from GlaxoSmithKline. The company was founded by Emiliangelo Ratti and Mike Trower in 2012 and is headquartered in Stevenage, the United Kingdom. | Director/Board Member | 26/09/2017 |
KaNDy Therapeutics Ltd.
KaNDy Therapeutics Ltd. BiotechnologyHealth Technology KaNDy Therapeutics Ltd. engages in the provision of a treatment of chronic debilitating female sex-hormone related conditions. Its product is NT-814 a non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms. The company was founded by Dr. Mike Trower and Mary Kerr in 2017 and is headquartered in Stevenage, the United Kingdom. | Director/Board Member | - |
NeRRe Therapeutics Holdings Ltd.
NeRRe Therapeutics Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services NeRRe Therapeutics Holdings Ltd. is a British biotechnology company founded in 2017. The private company is based in Stevenage, UK. The company is engaged in research and development of biotechnology. | Director/Board Member | 07/09/2017 |
Orphalan SA
Orphalan SA Pharmaceuticals: MajorHealth Technology GMP-Orphan SA engages in the research and development in biotechnology. It focuses on developing and designing drugs for life-threatening and rare diseases. The company was founded by Frederic Marin on July 18, 2011 and is headquartered in Paris, France. | Director/Board Member | - |
Former positions of Saiyed Mahmood
Companies | Position | End |
---|---|---|
Nicoventures Trading Ltd.
Nicoventures Trading Ltd. Industrial ConglomeratesProducer Manufacturing Nicoventures Trading Ltd. researches, develops, manufactures and delivers tobacco harm reduction products and services. The firm provides innovative and sustainable solutions to global problems arising from smoking and smoking-related illnesses. The company develops ortfolio of products and services focused on smoking cessation and harm reduction, including user-friendly nicotine delivery systems and patient-focused smoking cessation and support services. The company was founded by Christopher John Lord and David Thomas Newns in September 2008 and is headquartered in Manchester, the United Kingdom. | Director/Board Member | 17/12/2012 |
Cutfield Freeman & Co. Ltd.
Cutfield Freeman & Co. Ltd. Investment ManagersFinance Cutfield Freeman & Co. Ltd. provides independent advice on mining finance such as joint ventures, project finance, mergers and acquisitions, private fund raising, and corporate restructuring. The firm also develops and implements strategies to address complex mining finance challenges. The company was founded in 2000 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Axonics Women's Health Ltd.
Axonics Women's Health Ltd. Pharmaceuticals: MajorHealth Technology Contura Ltd. specializes in the distribution and sale of healthcare products, both in pharmaceuticals and medical devices. The firm focuses in the fields of urology and urogynaecology. Its products include bulkamid, cystistat, and aquamid. The company was founded by Henry Geoffrey McMillan in 2000 and is headquartered in London, the United Kingdom. | Director/Board Member | - |
Training of Saiyed Mahmood
University College London | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 9 |
---|---|
Advent Venture Partners LLP
Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Finance |
Cutfield Freeman & Co. Ltd.
Cutfield Freeman & Co. Ltd. Investment ManagersFinance Cutfield Freeman & Co. Ltd. provides independent advice on mining finance such as joint ventures, project finance, mergers and acquisitions, private fund raising, and corporate restructuring. The firm also develops and implements strategies to address complex mining finance challenges. The company was founded in 2000 and is headquartered in London, the United Kingdom. | Finance |
Axonics Women's Health Ltd.
Axonics Women's Health Ltd. Pharmaceuticals: MajorHealth Technology Contura Ltd. specializes in the distribution and sale of healthcare products, both in pharmaceuticals and medical devices. The firm focuses in the fields of urology and urogynaecology. Its products include bulkamid, cystistat, and aquamid. The company was founded by Henry Geoffrey McMillan in 2000 and is headquartered in London, the United Kingdom. | Health Technology |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Health Technology |
Nicoventures Trading Ltd.
Nicoventures Trading Ltd. Industrial ConglomeratesProducer Manufacturing Nicoventures Trading Ltd. researches, develops, manufactures and delivers tobacco harm reduction products and services. The firm provides innovative and sustainable solutions to global problems arising from smoking and smoking-related illnesses. The company develops ortfolio of products and services focused on smoking cessation and harm reduction, including user-friendly nicotine delivery systems and patient-focused smoking cessation and support services. The company was founded by Christopher John Lord and David Thomas Newns in September 2008 and is headquartered in Manchester, the United Kingdom. | Producer Manufacturing |
NeRRe Therapeutics Ltd.
NeRRe Therapeutics Ltd. Medical DistributorsDistribution Services NeRRe Therapeutics Ltd. provides clinical and pre clinical drugs for treatment of neuronal hypersensitivity. It develops neurokinin receptor antagonists acquired from GlaxoSmithKline. The company was founded by Emiliangelo Ratti and Mike Trower in 2012 and is headquartered in Stevenage, the United Kingdom. | Distribution Services |
Orphalan SA
Orphalan SA Pharmaceuticals: MajorHealth Technology GMP-Orphan SA engages in the research and development in biotechnology. It focuses on developing and designing drugs for life-threatening and rare diseases. The company was founded by Frederic Marin on July 18, 2011 and is headquartered in Paris, France. | Health Technology |
KaNDy Therapeutics Ltd.
KaNDy Therapeutics Ltd. BiotechnologyHealth Technology KaNDy Therapeutics Ltd. engages in the provision of a treatment of chronic debilitating female sex-hormone related conditions. Its product is NT-814 a non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms. The company was founded by Dr. Mike Trower and Mary Kerr in 2017 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
NeRRe Therapeutics Holdings Ltd.
NeRRe Therapeutics Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services NeRRe Therapeutics Holdings Ltd. is a British biotechnology company founded in 2017. The private company is based in Stevenage, UK. The company is engaged in research and development of biotechnology. | Commercial Services |
- Stock Market
- Insiders
- Saiyed Mahmood